Omalizumab: First Approved Anti-IgE Therapy for Multiple Food Allergies

Omalizumab is a novel treatment strategy for multiple food allergies. By increasing the tolerance to foods that induce allergies, patients may experience a reduced risk of immune-mediated reactions on accidental allergen exposure. Uncertainty remains about the ideal candidates for omalizumab, its comparative effectiveness, practical implementation, and long-term outcomes. Ongoing trials and future real-world data are expected to clarify these issues, including its impact on reducing anaphylaxis, ED visits, and hospitalizations. Patient-specific factors and available options should be discussed with the patient in the shared decision process as an essential component in choosing the therapeutic strategy.